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Abstract: In this study, the transdermal drug delivery properties of D,L-tetrahydropalmatine 
(THP)-loaded amphiphilic poly{[α-maleic anhydride-ω-methoxy-poly(ethylene glycol)]-
co-(ethyl cyanoacrylate)} (PEGECA) graft copolymer nanoparticles (PEGECAT NPs) were 
evaluated by skin penetration experiments in vitro. The transdermal permeation experiments 
in vitro were carried out in Franz diffusion cells using THP-loaded PEGECAT NPs as the donor 
system. Transmission electron microscopy and Fourier transform infrared spectroscopy were 
used to characterize the receptor fluid. The results indicate that the THP-loaded PEGECAT 
NPs are able to penetrate the rat skin. Fluorescent microscopy measurements demonstrate that 
THP-loaded PEGECAT NPs can penetrate the skin not only via appendage routes but also via epi-
dermal routes. This nanotechnology has potential application in transdermal drug delivery.
Keywords: poly{[α-maleic anhydride-ω-methoxy-poly(ethylene glycol)]-co-(ethyl 
cyanoacrylate)}, nanoparticles, transdermal drug delivery, D,L-tetrahydropalmatine
Introduction
Transdermal drug delivery has many advantages such as high patient compliance, no 
first-pass metabolism of drugs, and controlled delivery over long time periods compared 
to oral delivery or injection. However, the outer layer of skin, called stratum corneum 
with 10–15 µm multilayered wall-like structure, has impressive barrier properties and 
provides an excellent barrier between the external environment and internal body, 
which causes difficulties for drug delivery through the skin.1–3 Many methods have 
been developed to enhance percutaneous absorption of therapeutic agents.4–6 Chemical 
enhancers with high affinity with skin lipids that can change the structure of stratum 
corneum physically or chemically5,7 and delivery devices that can penetrate stratum 
corneum4,8 have been widely used. However, chemical enhancers and delivery devices 
usually cause skin damage and weaken the function of the skin barrier.
Delivery carriers such as micelles,9,10 liposomes,11 solid lipid nanoparticles 
(NPs),12,13 polymer and dendrimer NPs14,15 and inorganic NPs6 have been developed to 
improve percutaneous absorption of therapeutic agents while alleviating the damage 
to the skin. Due to the flexible modification of polymer structure and easy production, 
polymer NPs have potential applications in improving the transport efficiency of drugs 
and biomacromolecules through the skin. Cui and Mumper prepared DNA-loaded 
chitosan NPs and applied them to shaved rat skin, concluding that chitosan-based NPs International Journal of Nanomedicine 2009:4 228
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containing DNA resulted in both detectable and quantifiable 
levels of luciferase expression in rat skin 24 hours after 
topical application.16
Recently, amphiphilic copolymer NPs were studied for 
transdermal drug delivery. Shim and colleagues reported 
that the permeation of minoxidil incorporated in 40 nm 
NPs of poly(ε-caprolactone)-block-poly(ethylene glycol) 
(PCL-b-PEG) was 1.5-fold higher in the epidermal layer and 
1.7-fold higher in the receptor solution than that of 130 nm 
NPs of PCL-b-PEG when applied onto the skin of hairy 
pigs.17 In our lab, transdermal drug delivery properties of 
methoxy poly(ethylene glycol)-block-poly(D,L-lactic acid) 
(PEG-b-PDLLA) NPs by using paclitaxel as a model drug have 
been carefully studied. The PEG-b-PDLLA NPs can penetrate 
rat skin as integrated particles and efficiently transport pacli-
taxel through the skin. Previous reports indicate that amphi-
philic copolymer NPs are effective carriers for transdermal 
drug delivery.18 Previously, we reported that the preparation 
of poly{[α-maleic anhydride-ω-methoxy-poly(ethylene 
glycol)]-co-(ethyl cyanoacrylate)} (PEGECA) graft copoly-
mer and in vitro release property of D,L-tetrahydropalmatine 
(THP)-loaded PEGECA graft copolymer NPs (PEGECAT 
NPs).19,20 THP can be encapsulated into the hydrophobic core 
of PEGECAT NPs and the accumulated release is lower than 
40% after 48 hours. Whether PEGECAT NPs encapsulating 
drug can effectively deliver drug through the skin or not has 
not been investigated. In this study, we research the in vitro 
transdermal permeation behavior of THP-loaded PEGECAT 
NPs by using THP as a model drug.
Materials and methods
Materials
Poly{[α-maleic anhydride-ω-methoxy-poly(ethylene 
glycol)]-co-(ethyl cyanoacrylate)} (PEGECA) graft 
copolymer (Mn = 11600, MnPECA = 6600, MnPEG = 5000) was 
prepared as described previously.19 D,L-tetrahydropalmatine 
(THP) was supplied by Tongrentang Co. (Tianjin, China). 
Dichloromethane (DCM) and acetone were purchased from 
the Tianjin Chemical Reagent Co (Tianjin, China). All 
reagents were analytical grade and used as received.
Preparation of ThP-loaded 
PegecAT NPs
THP-loaded PEGECAT NPs were prepared by nanopre-
cipitation technique.20 Briefly, the drug was dissolved in 
PEGECAT solution in acetone, ie, 3 mg THP dissolved 
in 2 ml PEGECAT acetone solution at 50 mg/ml concen-
tration and then the mixture solution was added into 10 ml 
distilled water under magnetic stirring at ambient temperature 
and acetone was allowed to evaporate completely under 
agitation. The obtained dispersion was then centrifuged by a 
centrifuge (LD5-2A, Beijing, China) at 3000 rpm for 30 min 
in order to eliminate the aggregated particles. The supernatant 
was PEGECAT NPs dispersion, which was directly used 
for transmission electron microscopy (TEM) and particle 
size distribution. The supernatant could also be frozen and 
lyophilized by a freeze-dryer system (LGJ-10, Beijing, 
China) to obtain PEGECAT NPs freeze-dried powder, which 
can disperse into water to form NPs dispersions.
characterization of ThP-loaded 
PegecAT NPs
The TEM specimens for the THP-loaded PEGECAT 
NPs dispersions were observed under a JEM-100CX II 
instrument. The samples were prepared by adding a drop of 
the PEGECAT NPs dispersion on the Formvar-coated copper 
TEM grid, and then dyed by phosphotungstic acid. The size 
and distribution of PEGECAT NPs were determined by 
BI-90Plus laser particle size analyzer (LPSA; Brookhaven 
Instruments, Holtsville, NY, USA). For all cases, λ of mea-
surement was 678 nm, the angle of measurement was 90°, 
and the temperature of measurement was 25 °C.
In vitro permeation studies
Skin samples were obtained from adult Kunming rat 
(Tianjin Institute of Pharmaceutical Research, Tianjin, 
China). The subcutaneous fat tissue was removed before 
experiments. In vitro release was carried out at 37 °C with 
Franz diffusion cells (1 cm in diameter and 6 ml in receptor 
cell volume; Shishin Technology Co. Ltd, China). The recep-
tor compartments were filled with phosphate-buffered saline 
(PBS; pH = 7.4), containing 0.02% w/v of sodium azide to 
retard microbial growth, and the receptor phase was stirred 
with small magnetic beads to mix the contents uniformly. The 
skin pieces were carefully mounted onto the receiver compart-
ment of the diffusion cells with the stratum corneum facing in 
the direction of the donor compartment. Subsequently, 750 µl 
of donor solution was applied to the stratum corneum side in 
the donor compartment. Two kinds of donor phase used, each 
containing 6.19% THP, were supersaturated water solution of 
THP and THP-loaded PEGECAT NPs aqueous dispersion, 
respectively. After application of donor solution, 1 ml of 
sample was withdrawn from receptor compartments at the 
appropriate time intervals and the same amount of fresh PBS 
was supplemented into each receptor. Acetonitrile (1 ml) was 
added to the sample to dissolve both copolymer and THP fully International Journal of Nanomedicine 2009:4 229
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and the amount of THP in the sample was determined by 
high-pressure liquid chromatography (HPLC; Agillent1100, 
Agillet Co., USA) using a mobile phase of methanol, 7% 
acetic acid and 4% acetic acid ammonium (v/v/v, 40:31:29) 
at 1 ml/min with a Hypersil ODS-2 (250 × 4.6 mm) C18 
column.20 The receptor solution was collected after the in vitro 
experiments and freeze-dried. The lyophilized powder was 
pressed into KBr pellets and analyzed using Fourier transform 
infrared (FTIR) spectroscopy (FT3000, Bio-Rad Laboratories, 
Hercules, CA, USA). Morphological evaluation and size of 
the PEGECAT NPs in receptor solution were performed using 
TEM and LPSA, respectively.
Fluorescence microscopy
Pyrene-loaded PEGECAT NPs were also prepared by nano-
precipitation technique.20 The in vitro diffusion experiment 
was carried out according to the method mentioned above 
using an aqueous dispersion of pyrene-loaded PEGECAT 
NPs as donor phase. After the application period of 24 hours, 
excess dispersion was washed from the skin surface and the 
skin was removed and washed carefully with distilled water. 
Each specimen was frozen in liquid nitrogen. The specimens 
were subsequently sectioned vertically using a freeze-
microtome (CM 1850; Leica, Solms, Germany) and observed 
using fluorescence microscopy (DM RXA2; Leica).
Results and discussion
characterization of ThP-loaded 
PEGECAT NPs and receptor fluid
Before the transdermal permeation experiments, the particle 
size and morphology of THP-loaded PEGECAT NPs were 
characterized using TEM and LPSA as shown in Figure 1. 
THP-loaded PEGECAT NPs present spherical morphol-
ogy as shown in Figure 1a. Figure 1b shows that the mean 
particle size of the THP-loaded PEGECAT NPs before 
release is less than 100 nm. After the permeation experiment 
of THP-loaded PEGECAT NPs dispersion for 24 hours, 
the receptor fluid was directly detected using LPSA and 
TEM. The integrated particles observed in Figure 2a indi-
cate that THP-loaded PEGECAT NPs exist in the receptor 
compartment. It can be seen from Figure 2b that the particle 
size of the THP-loaded PEGECAT NPs in the receptor 
solution is larger than that of those in the donor, which 
might be due to the adsorption of protein or lipid in the 
skin. The receptor solution of the permeation experiment of 
THP-loaded PEGECAT NPs dispersion was collected and 
lyophilized into powder for FTIR analyses. It can be found 
from FTIR spectrum as shown in Figure 3 that a methylene-
characteristic band, a carbonyl band, a C–O stretching 
band, a C=N stretching band, and a C–O–C stretching band 
appear at 2929 cm−1, 1674 cm−1, 1128 cm−1, 2365 cm−1, and 
1082 cm−1, respectively. The FTIR result coupled with the 
TEM and LPSA results suggest that THP-loaded PEGECAT 
NPs can penetrate the rat skin.
In vitro permeation study
In order to evaluate the drug delivery ability of PEGECAT 
NPs, the skin permeation of THP from supersaturated water 
solution of THP and THP-loaded PEGECAT NPs aqueous 
dispersion was compared. No THP was detected in the recep-
tor solution when supersaturated water solution of THP was 
used as the donor fluid within 50 hours. The result indicates 
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Figure 1 A) TeM image and B) size distribution of PegecAT NPs loaded with 6.19% ThP before permeation experiment in vitro.
Abbreviations: PegecAT NPs, poly{[α-maleic anhydride-ω-methoxy-poly(ethylene glycol)]-co-(ethyl cyanoacrylate)} graft copolymer nanoparticles; TeM, transmission 
electron microscopy;   ThP, D,L-tetrahydropalmatine.International Journal of Nanomedicine 2009:4 230
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that THP itself is hard to permeate across the rat skin. 
However, THP was detected in the receptor solution when 
THP-loaded PEGECAT NPs aqueous dispersion was used 
as the donor fluid. It can be found from transdermal drug 
delivery kinetics of THP-loaded PEGECAT NPs as shown 
in Figure 4 that the rate of transdermal drug delivery is faster 
before 10 hours. The reason is that in the beginning stage 
NPs with small size can easily penetrate the skin. However, 
the stable channels for NPs with large size probably form 
after 10 hours duo to the tardy interaction between NPs and 
stratum corneum.
Investigation on the permeation routes
To confirm the routes that PEGECAT NPs penetrate the 
skin, the lipophilic fluorescent probe pyrene-loaded NPs 
were used to study skin penetration of PEGECAT NPs. 
It can be seen that the size of pyrene-loaded PEGECAT NPs 
is around 100 nm as shown in Figure 5a. An accumulation 
of fluorescence of pyrene-loaded PEGECAT NPs can be 
observed as shown in Figure 5b. Therefore, pyrene-loaded 
PEGECAT NPs can be used to investigate the permeation 
routes of PEGECAT NPs. Fluorescence micrographs pre-
sented in Figure 6 show the relative fluorescence intensity 
of the probe in the skin layers after applying an aqueous 
formulation of pyrene-loaded PEGECAT NPs to rat skin 
for 24 hours. An accumulation of fluorescence with even 
distribution can be clearly seen in both the upper layers of 
rat skin and deeper ones. Therefore, it can be concluded that 
PEGECAT NPs penetrate rat skin via appendage routes and 
epidermal routes.
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Figure 2 A) TeM image and B) size distribution of the particles in the receptor solution after 24 hours permeation experiment in vitro.
Abbreviation: TeM, transmission electron microscopy.
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Figure 3 FTIR spectrum of lyophilized powder of the receptor fluid after in vitro skin 
permeation experiment applying PegecAT NPs dispersion as the donor solution.
Abbreviations: FTIR, fourier transform infrared; PegecAT NPs, poly{[α-maleic 
anhydride-ω-methoxy-poly(ethylene glycol)]-co-(ethyl cyanoacrylate)} graft copolymer 
nanoparticles.
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Figure 4 In vitro permeation profiles of   THP from PEGECAT NPs dispersion through 
rat skin. Results are expressed as means ± sD of four different experiments.
Abbreviations: PegecAT NPs, poly{[α-maleic anhydride-ω-methoxy-poly(ethylene 
glycol)]-co-(ethyl cyanoacrylate)} graft copolymer nanoparticles; sD, standard 
deviation; ThP, D,L-tetrahydropalmatine.International Journal of Nanomedicine 2009:4 231
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Conclusions
D,L-tetrahydropalmatine-loaded  poly{[α-maleic 
anhydride-ω-methoxy-poly(ethylene glycol)]-co-(ethyl 
cyanoacrylate)} (PEGECA) graft copolymer nanopar-
ticles (PEGECAT NPs) with the size of less than 100 nm 
were prepared. D,L-tetrahydropalmatine-loaded PEGE-
CAT copolymer NPs can penetrate rat skin as integrated 
particles and efficiently deliver D,L-tetrahydropalmatine 
through the skin. The results of fluorescence microscopy 
demonstrate that the PEGECAT copolymer NPs penetrate 
the skin not only via appendage routes but also via epi-
dermal routes.
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